Fundamental Analysis Stories

<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#000000;color: #f2f2f2;font-size:0.9em;;'>LES</div>
  over two months ago at Macroaxis 
By Raphi Shpitalnik
Even with relatively steady forward indicators, Leslies is not utilizing all of its potentials. The latest stock price chaos, may contribute to a medium-term swings for the stakeholders. Will stakeholders continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:0.9em;;'>FEY</div>
  over two months ago at Macroaxis 
By Vlad Skutelnik
FireEye Free Cash Flow is projected to increase significantly based on the last few years of reporting. The past year's Free Cash Flow was at 21.93 Million. The current year Working Capital is expected to grow to about 476 M, whereas Revenue Per Employee is forecasted to decline to about 220.6 K. The next fiscal quarter end is expected on the 31st of December 2020. The stock experiences an active upward rally. While some of us are excited about technology space, let's try to digest FireEye in greater detail to make a better evaluation of its fundamental indicators. We will evaluate why we are still confident in anticipation of a recovery. We currently estimate FireEye as fairly valued. The real value is approaching 18.91 per share.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF0000;color: #F5FFFA;font-size:1.1em;;'>CC</div>
  over two months ago at Macroaxis 
By Vlad Skutelnik
CalAmp Corp Long Term Debt to Equity is very stable at the moment as compared to the past year. CalAmp Corp reported last year Long Term Debt to Equity of 1.28. As of 17th of December 2020, PPandE Turnover is likely to grow to 9.04, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (6.9 M). In spite of very healthy primary indicators, CalAmp Corp is not utilizing all of its potentials. The latest stock price disarray, may contribute to a short-term swings for the insiders. Will insiders continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#000000;color: #f2f2f2;font-size:1.1em;;'>AD</div>
  over two months ago at Macroaxis 
By Raphi Shpitalnik
Applied DNA Asset Turnover is quite stable at the moment as compared to the past year. The company's current value of Asset Turnover is estimated at 1.58. Current Ratio is expected to rise to 1.13 this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (7.8 M). One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will outline Applied DNA. We will look into reasons why it is still very possible for the company to generate above-average returns. The company barely shadows the market. We can now inspect Applied as a potential investment option for your portfolios.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#006400;color: #FFE4E1;font-size:1.1em;;'>ST</div>
  over two months ago at Macroaxis 
By Raphi Shpitalnik
Steelcase Book Value per Share is relatively stable at the moment as compared to the past year. Steelcase reported last year Book Value per Share of 7.41. As of 12/17/2020, Dividend Yield is likely to grow to 0.21, while Average Equity is likely to drop slightly above 1.2 B. Even with relatively invariable essential indicators, Steelcase is not utilizing all of its potentials. The current stock price agitation, may contribute to a short-term swings for the retail investors. We currently estimate Steelcase as overvalued. The real value is approaching 11.20 per share.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;;'>CE</div>
  over two months ago at Macroaxis 
By Achuva Shats
Centogene Capital Expenditure is projected to increase significantly based on the last few years of reporting. The past year's Capital Expenditure was at 21 Million. The current year Net Cash Flow or Change in Cash and Cash Equivalents is expected to grow to about 34.4 M, whereas Earnings before Tax are forecasted to decline to (21 M). Centogene NV is scheduled to announce its earnings today. The next earnings report is expected on the 22nd of April 2021. Many investors are getting excited about healthcare space, let's analyze if Centogene NV fundamentals are strong enough to attract traders. We will evaluate why we are still confident in anticipation of a recovery. Centogene NV odds of distress is under 15 percent. Will the firm shareholders continue to take over in January?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:1.1em;;'>OM</div>
  over two months ago at Macroaxis 
By Raphi Shpitalnik
OncoSec Medical Price to Book Value is relatively stable at the moment as compared to the past year. OncoSec Medical reported last year Price to Book Value of 6.97. As of 12/16/2020, Tangible Assets Book Value per Share is likely to grow to 1.86, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (43.2 M). OncoSec Medical Inco is scheduled to announce its earnings today. While some generation-Y investors are indifferent towards healthcare space, it makes sense to sum up OncoSec Medical Incorporated using its fundamentals . We will evaluate if OncoSec Medical shares are reasonably priced going into January. Will retail investors continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;;'>HC</div>
  over two months ago at Macroaxis 
By Achuva Shats
HEXO Corp is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 14th of December 2020. The stock is still going through a very aggressive trading activities. Healthcare space may be getting hot again, let's check if HEXO Corp is sending any bullish signals to investors. We will look into reasons why it is still very possible for the company to generate above-average returns. The company current probability of distress is under 3 percent. Will institutional investors continue to be optimistic, or should we expect a sell-off?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;;'>HJ</div>
  over two months ago at Macroaxis 
By Vlad Skutelnik
Hancock Jaffe Current Ratio is most likely to increase slightly in the upcoming years. The last year's value of Current Ratio was reported at 0.76. The current Debt to Equity Ratio is estimated to increase to 2.66, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease to (7.9 M). The stock just had it stock split. Hancock Jaffe has reported 1 for 25 split on 30th of November 2020. Although many conservative investors are getting more into healthcare space, we should study Hancock Jaffe's current fundamentals in more details. We will evaluate why we are still confident in anticipation of a recovery. Will stockholders continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#347AFC;color: #ffffff;font-size:0.9em;;'>ONC</div>
  over two months ago at Macroaxis 
By Raphi Shpitalnik
Even with relatively uncertain basic indicators, Oncorus may actually be approaching a critical reversion point that can send shares even higher in January 2021. We currently estimate Oncorus as undervalued. The real value is approaching 29.87 per share.